Scientists at Hebei Medical University have uncovered an unexpected link between the immune system and hearing, showing that a well-known chemokine receptor once thought to act mainly in inflammation is also a critical gatekeeper of electrical signaling in the ear. In a study published in Cell Death Discovery, the team reports that mice lacking CXCR2, a receptor for CXC chemokines, gradually lose their hearing because the spiral ganglion neurons that relay sound to the brain become far less excitable. The finding reframes a molecule best known for guiding immune cells toward sites of infection as an essential component of the auditory circuit itself.
CXCR2 belongs to the large family of G-protein-coupled receptors that detect chemokines, small signaling proteins that orchestrate the movement and activation of white blood cells. Because inflammation has been firmly implicated in noise-induced hearing loss, drug-induced ototoxicity, and age-related hearing decline, researchers have long suspected that chemokine signaling participates in auditory pathology. What remained unclear was whether CXCR2 plays an active role in the cells that actually carry out hearing, rather than merely responding to inflammatory damage. The new study set out to map where the receptor is expressed in the cochlea and what happens when it is removed.
The answer surprised the investigators. Using mouse models, they found CXCR2 abundantly expressed not only in expected immune-associated niches but in the cochlea’s core signal-processing machinery: the spiral ganglion neurons, the hair cells that convert mechanical vibration into electrical signals, and the stria vascularis, the vascular tissue that maintains the ionic environment required for hair cell function. This distribution placed the receptor squarely inside the pathway that every sound must travel before it can reach the auditory cortex.
When the researchers genetically deleted CXCR2, the consequences were unambiguous. The knockout mice developed progressive hearing loss, meaning their auditory thresholds worsened over time rather than failing abruptly. Progressive deterioration is a hallmark of degenerative auditory disease, and its appearance in otherwise healthy animals pointed to an intrinsic defect in how the cochlea maintains its own function, not simply an acute injury.
To understand the mechanism, the team examined the spiral ganglion neurons in detail, and the molecular changes they documented form a coherent picture of a neuron being retuned toward silence. The knockout neurons showed increased expression of the Kv1.2 potassium channel, a voltage-gated channel that allows potassium ions to flow out of the cell when the membrane depolarizes. Potassium efflux through Kv1 channels is one of the main forces that pull a neuron’s membrane potential back down after it fires, so upregulating Kv1.2 effectively raises the barrier that an incoming signal must overcome before the neuron will generate an action potential.
Electrophysiological recordings confirmed the functional consequence. CXCR2-deficient spiral ganglion neurons exhibited enhanced Kv1 currents, and their overall excitability was significantly reduced. In practical terms, the same synaptic input that would reliably drive a healthy spiral ganglion neuron to fire produced weaker, less reliable responses in the knockout neurons. Because the spiral ganglion is the sole conduit between the cochlea’s mechanosensory hair cells and the central auditory system, a systematic dampening of its excitability translates directly into diminished hearing sensitivity, even if the hair cells themselves remain intact.
The structural correlates of this functional decline were equally telling. The knockout mice showed impaired ribbon synapses, the specialized presynaptic structures that allow hair cells to transmit neurotransmitter continuously and with remarkable temporal precision onto the spiral ganglion neuron fibers. Ribbon synapses are essential for the faithful encoding of sound timing and intensity, and their degradation is a recognized substrate of hidden hearing loss. The team also documented altered myelin integrity in the auditory nerve, which would be expected to slow and destabilize the conduction of action potentials along the nerve fibers, compounding the deficit created at the synapse.
Perhaps the most clinically consequential result came from a rescue-style experiment conducted in the opposite direction. Rather than relying solely on germline knockout animals, which can accumulate compensatory developmental changes, the researchers used an adeno-associated virus vector to knock down CXCR2 specifically within the spiral ganglion neurons of otherwise normal mice. This targeted intervention recapitulated the hearing loss phenotype, demonstrating that the receptor’s role in the neurons themselves is sufficient to explain the auditory deficit. The experiment rules out the possibility that the knockout phenotype is merely a byproduct of systemic inflammation or developmental rewiring elsewhere in the body, and it localizes the causal mechanism to the auditory neurons.
The study’s implications extend in two directions. For basic neuroscience, it adds CXCR2 to the growing list of immune molecules that have been co-opted by the nervous system for housekeeping duties far removed from host defense, in this case the tuning of ion channel expression and synaptic architecture in a sensory pathway. For translational research, it suggests that patients with inflammatory auditory disorders may be experiencing not only damage from immune overactivation but also disruption of a receptor that the cochlea needs for normal electrical signaling. Therapies that modulate chemokine signaling, which are already being explored in inflammatory and neurological disease, may therefore need to account for effects on the inner ear that have not previously been considered.
The work also raises questions that the authors and the field will now need to pursue. Which chemokine ligands engage CXCR2 in the cochlea, and under what physiological conditions? Does the receptor’s influence on Kv1.2 expression operate through transcriptional regulation of the channel gene or through trafficking of existing channels to the membrane? And could restoring CXCR2 signaling in a degenerating cochlea reverse the excitability deficit, or would the ribbon synapse and myelin damage prove irreversible? Answering these questions will determine whether CXCR2 becomes a viable therapeutic target or remains an important clue to how the auditory system maintains its extraordinary precision over a lifetime. Either way, the study establishes that hearing depends on a molecule the immunology textbooks had claimed for themselves, and it adds a new dimension to the understanding of how inflammation and neural function intersect in the inner ear.
Subject of Research: The role of the chemokine receptor CXCR2 in regulating spiral ganglion neuron excitability and auditory function
Article Title: CXCR2 deficiency impairs auditory function in spiral ganglion neurons by altering excitability
Article References: Xian, F., Ma, X., Zhang, Z., He, C., Li, Z., Liu, J., Jin, X., Xiao, J., Shen, H., & Lv, P. (2026). CXCR2 deficiency impairs auditory function in spiral ganglion neurons by altering excitability. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03366-7
Image Credits: AI Generated
DOI: 10.1038/s41420-026-03366-7
Keywords: CXCR2, hearing loss, spiral ganglion neurons, cochlea, potassium channels, Kv1.2, ribbon synapses, electrophysiology, chemokine receptor, auditory neuroscience, inflammation, mouse models
News Source: Drew Townsend. (October 16, 2026). Missing Immune Receptor Silences the Ear’s Nerve Cells and Drives Hearing Loss. Scienmag.
